SG11202107877WA - Platinum-based amphiphile prodrugs - Google Patents

Platinum-based amphiphile prodrugs

Info

Publication number
SG11202107877WA
SG11202107877WA SG11202107877WA SG11202107877WA SG11202107877WA SG 11202107877W A SG11202107877W A SG 11202107877WA SG 11202107877W A SG11202107877W A SG 11202107877WA SG 11202107877W A SG11202107877W A SG 11202107877WA SG 11202107877W A SG11202107877W A SG 11202107877WA
Authority
SG
Singapore
Prior art keywords
prodrugs
platinum
amphiphile
based amphiphile
amphiphile prodrugs
Prior art date
Application number
SG11202107877WA
Other languages
English (en)
Inventor
Minoo Jalili Moghaddam
Xiaojuan Gong
Ross Cyril Smith
Original Assignee
NanoMed Holdings Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902222A external-priority patent/AU2018902222A0/en
Application filed by NanoMed Holdings Pty Ltd filed Critical NanoMed Holdings Pty Ltd
Publication of SG11202107877WA publication Critical patent/SG11202107877WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202107877WA 2018-06-21 2019-06-21 Platinum-based amphiphile prodrugs SG11202107877WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018902222A AU2018902222A0 (en) 2018-06-21 Platinum-based amphiphile prodrugs
PCT/AU2019/050646 WO2019241853A1 (en) 2018-06-21 2019-06-21 Platinum-based amphiphile prodrugs

Publications (1)

Publication Number Publication Date
SG11202107877WA true SG11202107877WA (en) 2021-08-30

Family

ID=68982513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107877WA SG11202107877WA (en) 2018-06-21 2019-06-21 Platinum-based amphiphile prodrugs

Country Status (5)

Country Link
US (1) US20210275489A1 (ja)
EP (1) EP3810622A4 (ja)
JP (2) JP2021527675A (ja)
SG (1) SG11202107877WA (ja)
WO (1) WO2019241853A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115590879B (zh) * 2021-06-28 2024-03-22 沈阳药科大学 一种铂类药物脂质衍生物及其应用
CN116621900B (zh) * 2023-01-10 2024-05-07 河南大学 一种基于调控Mucin型O-糖基化靶向CRPC的四价铂氨基己糖配合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229640T2 (de) 1991-10-04 1999-12-16 Gs Dev Ab Malmoe Teilchen, methode zur herstellung der teilchen und deren verwendung
US5648384A (en) * 1993-10-04 1997-07-15 Tanaka Kikinzoku Kogyo K.K. Anti-tumor platinum (IV) complex
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
WO2006098496A1 (ja) 2005-03-18 2006-09-21 The University Of Tokyo ジアミノシクロヘキサン白金(ii)とブロック共重合体との配位化合物及びそれを含有する抗がん剤
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
CN104936622B (zh) * 2012-12-28 2019-05-28 塔弗达治疗有限公司 包封在颗粒中的靶向缀合物及其制剂
US9738672B2 (en) * 2013-12-31 2017-08-22 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
CN106471006B (zh) * 2014-05-02 2020-04-24 耶路撒冷希伯来大学伊森姆研究发展有限公司 Pt(IV)衍生物以及包含其的纳米载体
EP3397643A1 (en) * 2015-12-30 2018-11-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pt(IV) PRODRUGS
GB2548084A (en) * 2016-02-26 2017-09-13 Midatech Ltd Nanoparticle production
CN109021026B (zh) * 2018-07-18 2021-04-02 浙江大学 顺铂药物前体、制备方法和应用

Also Published As

Publication number Publication date
EP3810622A1 (en) 2021-04-28
JP2021527675A (ja) 2021-10-14
US20210275489A1 (en) 2021-09-09
WO2019241853A1 (en) 2019-12-26
EP3810622A4 (en) 2022-04-06
JP2023145470A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
CA187446S (en) Earbud case
IL278970A (en) CNP drug dispensers
EP3394080A4 (en) LIPID-LINKED PRODRUGS
EP3297586A4 (en) ORAL DEVICE
IL265588A (en) Treprostinil prodrugs
ZA202107278B (en) Abiraterone prodrugs
HK1243079A1 (zh) 水溶性前藥
HK1247576A1 (zh) 氧雜二環庚烷前藥
CA184840S (en) Grater
EP4081283C0 (en) AEROSOL GENERATOR COMPRISING MULTIPLE POWER ELEMENTS
EP3755363C0 (en) PLANTARICIN NC8ALPHA-BETA VARIANTS
PL3380552T3 (pl) Bchpc o zmniejszonej szybkości spalania
SG11202107877WA (en) Platinum-based amphiphile prodrugs
PT3266318T (pt) Pão sem açúcar
PT3360866T (pt) Pró-fármacos de mirabegrom
ZA201906271B (en) Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament
EP3784681A4 (en) GEMCITABIN AMPHIPHIL PRODRUGS
AU2018902222A0 (en) Platinum-based amphiphile prodrugs
GB201808537D0 (en) Prodrugs
AU2018901386A0 (en) Gemcitabine Amphiphile prodrugs
AU2018901352A0 (en) Gemcitabine Amphiphile prodrugs
GB2579397B (en) Bread manufacture
GB2595347B (en) Bread manufacture
EP4055525A4 (en) ARBITRARY VIEW GENERATION
GB201708458D0 (en) Prodrugs